Journal article
Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness
Stellenbosch University1
University of Pittsburgh2
Flux Optimisation and Bioanalytics, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark3
Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark4
Technical University of Denmark5
BioCODE Technologies6
Mediclinic Stellenbosch7
Northwestern University8
Henry Ford Health System9
St. Joseph Regional Medical Center10
Indiana University Bloomington11
University of Colorado Anschutz Medical Campus12
Denver Health13
...and 3 moreEarlier variants of SARS-CoV-2 have been associated with hypercoagulability and an extensive formation of fibrin amyloid microclots, which are considered to contribute to the pathology of the coronavirus 2019 disease (COVID-19). The newer omicron variants appear to be far more transmissible, but less virulent, even when taking immunity acquired from previous infections or vaccination into account.
We here show that while the clotting parameters associated with omicron variants are significantly raised over those of healthy, matched controls, they are raised to levels significantly lower than those seen with more severe variants such as beta and delta. We also observed that individuals infected with omicron variants manifested less extensive microclot formation in platelet-poor plasma compared with those harboring the more virulent variants.
The measurement of clotting effects between the different variants acts as a kind of internal control that demonstrates the relationship between the extent of coagulopathies and the virulence of the variant of interest. This adds to the evidence that microclots may play an important role in reflecting the severity of symptoms observed in COVID-19.
Language: | English |
---|---|
Publisher: | Thieme Medical Publishers, Inc. |
Year: | 2022 |
Pages: | 858-868 |
ISSN: | 10989064 and 00946176 |
Types: | Journal article |
DOI: | 10.1055/s-0042-1756306 |
ORCIDs: | Kell, Douglas B. and 0000-0002-9108-2384 |
COVID-19 Coagulation Fluorescence microscopy Microclots Omicron SDG 3 - Good Health and Well-being Variants
Fibrin Humans SARS-CoV-2 coagulation fluorescence microscopy microclots variants